BioCentury
ARTICLE | Company News

Kitov, Kuhnil deal

March 17, 2017 4:26 PM UTC

Kitov granted Kuhnil exclusive South Korean rights to develop and commercialize KIT-302. Kitov is eligible for undisclosed regulatory milestones and double-digit royalties. Kuhnil will be responsible for obtaining regulatory approval in South Korea and expects to launch the product in 2019...